CD101 IV

Cidara Therapeutics Inc. · Phase 1 active Small molecule

At a glance

Generic name	CD101 IV
Sponsor	Cidara Therapeutics Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Single Ascending Dose Study of CD101 IV in Healthy Subjects (PHASE1)
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension (PHASE2)
An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CD101 IV CI brief — competitive landscape report
CD101 IV updates RSS · CI watch RSS
Cidara Therapeutics Inc. portfolio CI